Vaccine. PolyI:polyC12U adjuvant-combined intranasal vaccine protects mice against highly pathogenic H5N1 influenza virus variants.

[Giuseppe]

Vaccine. 2009 Oct 23;27(45):6276-9.

PolyIolyC12U adjuvant-combined intranasal vaccine protects mice against highly pathogenic H5N1 influenza virus variants.

Ichinohe T, Ainai A, Tashiro M, Sata T, Hasegawa H. - Department of Pathology, National Institute of Infectious Diseases, 4-7-1 Gakuen, Musashimurayama-shi, Tokyo, Japan.

The highly pathogenic avian H5N1 influenza virus has the potential to incite a global pandemic. Therefore, there is an urgent need to develop effective vaccines against these viruses. Because it is difficult to predict which strain of influenza will cause a pandemic, it is advantageous to develop vaccines that will confer cross-protective immunity against variants of the influenza virus. Recently, we reported that the Toll-like receptor 3 agonist, polyIolyC(12)U (Ampligen), has been proven to be safe in a Phase III human trial, and is an effective mucosal adjuvant for intranasal H5N1 influenza vaccination. Intranasal administration of an Ampligen adjuvanted pre-pandemic H5N1 vaccine (NIBRG14), which was derived from the A/Vietnam/1194/2004 strain, resulted in the secretion of vaccine-specific IgA and IgG in nasal mucosa and serum, respectively, and protected mice against homologous A/Vietnam/1194/2004 and heterologous A/Hong Kong/483/97 and A/Indonesia/6/2005 viral challenge.

PMID: 19840660 [PubMed - in process]

-
------

 

[mixin]

Re: Vaccine. PolyIolyC12U adjuvant-combined intranasal vaccine protects mice against highly pathogenic H5N1 influenza virus variants.

We've been following Ampligen for several years now and it seems to have a lot of good test results. Back in June, Hemispherx was waiting for FDA approval for Ampligen for the management of Chronic Fatigue Syndrome.

I wonder if they continued with the clinical studies to increase the potency of Tamiflu and Relenza? With such limited stockpiles, this could have been really beneficial.

2006: Preclinical studies indicated that Tamiflu, when combined with Ampligen, achieved full inhibition of the H5N1 virus using just 1% to 2% of the Tamiflu needed to combat the virus on its own.

The tiny Philadelphia-based biotech presented the findings on Thursday in Washington, D.C., at a biodefense conference hosted by the American Society for Microbiology.

Hemispherx (amex: HEB - news - people ) also reported the potency of Relenza was increased by 500 times in lab experiments.

http://www.flutrackers.com/forum/showthread.php?t=457&highlight=Ampligen